FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL						
OMB Number:	3235-0104					
Expires: December 20						
Estimated average burden						
hours per response:	0.5					

MUELLER PETER (Mo		Date of Event F tatement Month/Day/Year)	· • [3. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]						
(Street)	(First)	(Middle)	7/15/2003		4. Relationship of Reporting Person(s (Check all applicable) Director X Officer (give title below) CSO & CSO	10% Owner Other (specibelow)	(M	If Amendment, Date of Original Filed (Month/Day/Year) Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person		
Table I - Non-Derivative Securities Beneficially Owned										
				eneficially Owned (Instr. 4)			4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable at Expiration Date (Month/Day/Year)		ate	Derivative Security (Instr. 4) Conv. or Ex.		Conversion or Exercise	Form: Direct	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
		Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	(D) or Indirect (I) (Instr. 5)			
Stock Option			10/15/2003 ⁽¹⁾	07/14/2013	Common Stock	200,000	16.32	D		

Explanation of Responses:

1. Right to buy under 1996 Stock and Option Plan vesting in 20 equal quarterly installments from 07-15-03.

Valerie L. Andrews, Atorney-In-

<u>Fact</u>

** Signature of Reporting Person

07/23/2003

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

CONFIRMING STATEMENT of Signature Authority

This Statement confirms that the undersigned has authorized and designated Kenneth S. Boger, Valerie L. Andrews, Michelle O. Rosen and Anne L. Bruno, and each of them acting alone, to execute and file on behalf of the undersigned any and all Forms 3, 4 and 5 (including any amendments thereto) that the undersigned may be required to file with the United States Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Vertex Pharmaceuticals Incorporated. The authority of Kenneth S. Boger, Valerie L. Andrews, Michelle O. Rosen and Anne L. Bruno under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4 or 5 with regard to the undersigned's ownership of or transactions in securities of Vertex Pharmaceuticals Incorporated, unless earlier revoked in writing. The undersigned acknowledges that Kenneth S. Boger, Valerie L. Andrews, Michelle O. Rosen and Anne L. Bruno are not assuming, nor is Vertex Pharmaceuticals Incorporated assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Act of 1934.

This Statement supersedes and replaces any earlier dated Statement that the undersigned has executed.

By: /s/ Peter Mueller

Date: July 15, 2003